Evidence map›Paper›PMID 38435492›Full record

ArticleAnnals of surgical treatment and research2024

Pioneering PGC-1α-boosted secretome: a novel approach to combating liver fibrosis.

Chang Ho Seo, Gun Hyung Na, Dosang Lee, Jung Hyun Park, Tae Ho Hong, Ok-Hee Kim, Sang Chul Lee, Kee-Hwan Kim, Ho Joong Choi, Say-June Kim

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical treatment and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Chang Ho SeoDepartment of Surgery, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-5260-9844
Gun Hyung NaDepartment of Surgery, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-1004-044X
Dosang LeeDepartment of Surgery, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-1528-2317
Jung Hyun ParkCatholic Central Laboratory of Surgery, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0003-2693-0655
Tae Ho HongDepartment of Surgery, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0003-3864-8104
Ok-Hee KimCatholic Central Laboratory of Surgery, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-9204-2587
Sang Chul LeeDepartment of Surgery, Daejeon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-8681-7059
Kee-Hwan KimCatholic Central Laboratory of Surgery, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-6219-6027
Ho Joong ChoiDepartment of Surgery, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-0862-098X
Say-June KimDepartment of Surgery, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-5171-4837
Catholic University of Korea · KRKorea Pharma (South Korea) · KRSt. Mary's Hospital · USThe Catholic University of Korea Bucheon St. Mary's Hospital · KRThe Catholic University of Korea Uijeongbu St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Liver fibrosis is a critical health issue with limited treatment options. This study investigates the potential of PGC-Sec, a secretome derived from peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)-overexpressing adipose-derived stem cells (ASCs), as a novel therapeutic strategy for liver fibrosis. Methods: Upon achieving a cellular confluence of 70%-80%, ASCs were transfected with pcDNA-PGC-1α. PGC-Sec, obtained through concentration of conditioned media using ultrafiltration units with a 3-kDa cutoff, was assessed through Results: Conclusion: These findings highlight the therapeutic potential of PGC-Sec in combating liver fibrosis by enhancing mitochondrial biogenesis and function, and promoting antifibrotic processes. PGC-Sec holds promise as a novel treatment strategy for liver fibrosis.

Indexed as

Adipose-derived stem cellsLiver fibrosisPeroxisome proliferator-activated receptor-gamma coactivator-1 alphaSecretome

Identifiers

PMID38435492
PMCPMC10902621
OpenAlexW4392833785

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.